horizon pharma plc (HZNP) Key Developments
Horizon Pharma Seeks Acquisitions
Apr 13 15
Horizon Pharma plc (NasdaqGS:HZNP) is planning to sell 12 million ordinary shares in an underwritten public offering. Horizon Pharma will use the proceeds to fund a portion of acquisition of Hyperion Therapeutics by the company and the remainder to fund additional acquisitions or investments in businesses, products and product candidates that are complementary to the company, and for general corporate purposes.
Horizon Pharma plc, Hyperion Therapeutics, Inc. - M&A Call
Mar 30 15
To review definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis and related matters
Horizon Pharma Mulls Acquisitions
Mar 30 15
Horizon Pharma plc is seeking acquisitions. Bob Carey, Executive Vice President and Chief Business Officer of Horizon Pharma plc said in Horizon Pharma Call, “We remain well positioned to drive revenue, and we will continue to seek additional acquisition opportunities to further leverage our business model and optimize our commercial infrastructure.”
Horizon Pharma plc Announces Pre-Clinical Data Show Treatment with Interferon Gamma Improved Signs of Disease Severity of Rare Bone Disease
Mar 7 15
Horizon Pharma plc announced that pre-clinical data from an investigator initiated study demonstrated that treatment with murine interferon gamma, which is an analogue of interferon gamma-1b (ACTIMMUNE), improved the signs of disease severity in a mouse model of Autosomal Dominant Osteopetrosis Type II (ADO2). Osteopetrosis is typically divided into two categories: autosomal recessive osteopetrosis or severe malignant osteopetrosis and autosomal dominant osteopetrosis (further divided into Type I and II (ADO2)). ADO2 is a rare, inherited disease resulting from a gene mutation that, despite an increased bone mass, is characterized by a wide range of symptoms and severity including multiple fractures, impaired vision and osteomyelitis (bone infection). ADO2 is the most common type of Autosomal Dominant Osteopetrosis with an estimated prevalence of up to 5.5 per 100,000. This disease has limited treatment options and as reflected in this study, treatment with calcitriol has not resulted in much clinical improvement. The pre-clinical study evaluated the effect of murine interferon gamma in a knock-in mouse model of the p.G213R mutation in the murine CLCN7 gene that results in severe osteopetrosis and death in homozygous (identical gene pairs) mice and a moderately severe form of osteopetrosis in heterozygous (different gene pairs) mice. Mice (n=10/group) were administered either placebo or varying doses (low, medium, high) of interferon gamma or calcitriol (a form of vitamin D) five times per week for 8 weeks. At the end of the eight-week treatment, X-ray and microcomputed tomography showed that treatment with interferon gamma significantly (p < 0.005) reduced the increase of whole body areal bone mineral density, an important measure of bone strength, across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. Additionally, interferon gamma treatment significantly reduced (p < 0.05) the bone volume over tissue volume gain across all dosing regimens in both male and female ADO2 mice compared to the vehicle group. In contrast, mice treated with low and medium doses of calcitriol showed a trend of higher bone mass including whole body areal bone mineral density and bone volume over tissue volume gain whereas the high dose calcitriol group significantly increased areal bone mineral density and bone volume over tissue volume gain compared to the placebo group. Autosomal Dominant Osteopetrosis Type II is a devastating disease and while these data are early, the findings may be important in exploring future treatment. ACTIMMUNE is approved for severe malignant osteopetrosis, the autosomal recessive form, and often the most severe form of osteopetrosis. Horizon is committed to exploring the full clinical utility of ACTIMMUNE and furthering potential treatment options where unmet needs exist for patients with osteopetrosis.
Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes
Mar 6 15
Horizon Pharma plc priced its offering of $350 million aggregate principal amount of Exchangeable Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The size of the offering was increased from the previously announced $300 million aggregate principal amount. The Issuer has also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50 million aggregate principal amount of the notes. The sale of the notes is expected to close on March 13, 2015, subject to customary closing conditions. The Issuer expects that the net proceeds from this offering will be approximately $338.0 million, after deducting the initial purchasers' discount and estimated offering expenses payable by the Issuer. The notes will be general unsecured senior obligations of the Issuer and accrue interest at an annual rate of 2.50% payable semiannually in arrears on March 15 and September 15 of each year, beginning on September 15, 2015. The notes will mature on March 15, 2022, unless earlier exchanged, repurchased or redeemed.